Cargando…
Shrink pattern of breast cancer after neoadjuvant chemotherapy and its correlation with clinical pathological factors
BACKGROUND: Breast conservation therapy (BCS) after neoadjuvant chemotherapy (NCT) can improve patients’ quality of life. Currently used intraoperative examination for negative margins may not be sufficient to detect microresidual foci, which are a risk factor for local recurrence. This study was co...
Autores principales: | Wang, Shushu, Zhang, Yi, Yang, Xinhua, Fan, Linjun, Qi, Xiaowei, Chen, Qingqiu, Jiang, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3728037/ https://www.ncbi.nlm.nih.gov/pubmed/23883300 http://dx.doi.org/10.1186/1477-7819-11-166 |
Ejemplares similares
-
PIK3CA mutations are associated with pathologic complete response rate to neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2-positive breast cancer
por: Shi, Qiyun, et al.
Publicado: (2022) -
Neoadjuvant Chemotherapy Creates Surgery Opportunities For Inoperable Locally Advanced Breast Cancer
por: Wang, Minghao, et al.
Publicado: (2017) -
Association between the spread of circulating tumor cells and breast cancer subtypes
por: Qi, Xiaowei, et al.
Publicado: (2010) -
Neoadjuvant Pyrotinib plus Trastuzumab and Chemotherapy for Stage I–III HER2‐Positive Breast Cancer: A Phase II Clinical Trial
por: Xuhong, Juncheng, et al.
Publicado: (2020) -
Lobaplatin-based neoadjuvant chemotherapy for triple-negative breast
cancer: a 5-year follow-up of a randomized, open-label, phase II
trial
por: Yan, Wenting, et al.
Publicado: (2022)